Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC5 | O15392 | 1/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.71 |
| ▸ | SP1 | P08047 | 1/20 | 0.71 |
| ▸ | ILF3 | Q12906 | 1/20 | 0.71 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.71 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepantronium SCHEMBL6188375 | 1.00 | BIRC5 (0.71) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL16584072 | 0.99 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL29379252 | 0.99 | BIRC5 (0.73) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6187056 | 0.89 | BIRC5 (0.58) | BIRC5RIPK2SP1ILF3PAK1 | |
| Bromide SCHEMBL22413046 | 0.89 | BIRC5 (0.61) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6189328 | 0.88 | BIRC5 (0.55) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6190071 | 0.86 | BIRC5 (0.74) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL2814447 | 0.84 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| Sepantronium SCHEMBL2814857 | 0.84 | BIRC5 (0.98) | BIRC5RIPK2SP1ILF3PAK1 | |
| SCHEMBL6189706 | 0.83 | BIRC5 (0.54) | BIRC5RIPK2SP1ILF3PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-12422437-B2 | Methods of screening for condensate-associated specificity and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2025082503-A1 | APOPTOSIS INHIBITOR MOLYBDATE SALTS FOR TREATING CANCER | JIANG CHUN (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025081428-A1 | APOPTOSIS INHIBITOR MOLYBDATE SALTS FOR TREATING CANCER | JIANG CHUN (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-118571331-B | Construction method of telomere related gene expression prediction model, product and application thereof | 南京林业大学 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| CN-118571331-A | Construction method of telomere related gene expression prediction model, product and application thereof | 南京林业大学 | 2024-08-30 | — | — | CN | disclosed |
| US-20240203555-A1 | METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN | SCIPHER MEDICINE CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240153580-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | Scipher Medicine Corporation | 2024-05-09 | — | — | US | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-20230053688-A1 | METHODS TO ALTER LATENCY IN EBV+ MALIGNANCIES | CORNELL UNIVERSITY | 2023-02-23 | — | — | US | disclosed |
| US-20220365093-A1 | METHODS OF SCREENING FOR CONDENSATE-ASSOCIATED SPECIFICITY AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220168316-A1 | METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS | CAMP4 THERAPEUTICS CORPORATION | 2022-06-02 | — | — | US | disclosed |
| US-11340231-B2 | Methods of screening for condensate-associated specificity and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11266655-B2 | Methods and compositions for treating urea cycle disorders | CAMP4 THERAPEUTICS CORPORATION (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | BIRC5 1753/4885RIPK2 2194/4885SP1 4224/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | BIRC5 695/4885RIPK2 293/4885SP1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.